Misyo (Methadone Hydrochloride)

Methadone, the active ingredient in Misyo, is an opioid analgesic presented as an oral formulation for oral use. It is employed in the maintenance treatment of opioid dependence and for the management of severe chronic pain in adults.

GNH USA supplies Misyo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methadone acts on the opioid system to address dependence and pain conditions. - Opioid dependence: provides maintenance therapy that reduces cravings and withdrawal symptoms. - Severe chronic pain: offers long‑acting analgesia for patients requiring continuous opioid control. - Opioid detoxification: facilitates supervised withdrawal by mitigating acute withdrawal signs.

Methadone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel motility. - Sweating: excessive perspiration. - Drowsiness: increased sleepiness. - Dry mouth: reduced salivation. - Headache: mild to moderate pain.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - QT interval prolongation: cardiac rhythm disturbance. - Seizures: convulsive episodes. - Severe hypotension: dangerously low blood pressure. - Allergic reactions: rash, itching, or anaphylaxis. - Adrenal insufficiency: impaired cortisol production.

When prescribing or dispensing Misyo, several safety considerations are essential. - Assess patient history: evaluate prior opioid use and tolerance. - Monitor cardiac function: watch for QT prolongation, especially in patients with cardiac risk factors. - Avoid use in acute respiratory distress: methadone can worsen breathing problems. - Use caution in hepatic impairment: liver disease may alter drug metabolism. - Educate about dependence risk: patients should understand the potential for addiction. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Methadone interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines): may cause profound respiratory depression. - MAO inhibitors: increase risk of serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise methadone plasma levels. - Other opioids: additive opioid effect leading to overdose. - QT‑prolonging agents (e.g., certain antiarrhythmics): heighten cardiac risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce methadone effectiveness. - Serotonergic drugs (e.g., SSRIs): monitor for serotonin syndrome signs. - Alcohol: enhances sedative effects. - Antihistamines: may increase drowsiness. - Some antiretrovirals: require plasma level monitoring.